Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - blóðþurrðandi lyf - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

viatris limited - síldenafílsítrat - háþrýstingur, lungnabólga - Þvaglát - adultstreatment fullorðinna sjúklinga með lungum háþrýsting flokkast sem hagnýtur ii og iii, til að bæta æfing getu. verkun hefur verið sýnd í frumum lungnaháþrýstingi og lungnaháþrýstingi sem tengist bandvefssjúkdómum. börn populationtreatment af börnum sjúklinga á aldrinum 1 ár til 17 ára gamall með lungum háþrýsting. verkun með tilliti til endurbóta á æfingargetu eða lungnablóðþrýstingi hefur sést við frumháþrýstingi og lungnaháþrýstingi sem tengist meðfæddan hjartasjúkdóm (sjá kafla 5.

Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris limited - amoxicillinum tríhýdrat - tafla - 750 mg

Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris limited - amoxicillinum tríhýdrat - hart hylki - 500 mg

Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

viatris limited - glargíninsúlín - sykursýki - lyf notuð við sykursýki - meðferð sykursýki hjá fullorðnum, unglingum og börnum 2 ára og eldri.

Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - augnlækningar - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.

Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris limited - atenololum inn - filmuhúðuð tafla - 50 mg

Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris limited - atenololum inn - filmuhúðuð tafla - 25 mg

Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris limited - adrenalinum bítartrat (epinephrinum bítartrat) - stungulyf, lausn - 1 mg/ml

Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris limited - ephedrini chloridum - stungulyf, lausn - 50 mg/ml